Sermorelin for Pediatric GHD

What Is Sermorelin and Why Is It Used Off-Label in Children?

Sermorelin acetate is a synthetic analog of the first 29 amino acids of human growth hormone-releasing hormone (GHRH[1-29]). It stimulates the pituitary gland to produce and secrete endogenous growth hormone rather than replacing GH directly. This mechanism preserves the physiologic pulsatility of GH release and the negative feedback loop that exogenous GH injections bypass [1].

The FDA originally approved sermorelin (brand name Geref) in 1997 for both diagnostic evaluation of pituitary GH secretory capacity and treatment of idiopathic growth hormone deficiency in children with open epiphyses [2]. EMD Serono voluntarily discontinued Geref in 2008 for commercial reasons, not safety concerns. The Endocrine Society's 2016 clinical practice guideline on pediatric GH deficiency does not include sermorelin among recommended therapies, noting the absence of post-marketing comparative data against modern rhGH formulations [3].

Today, pediatric endocrinologists who prescribe sermorelin do so off-label via compounding pharmacies. The rationale centers on three perceived advantages: preservation of GH pulsatility, lower antibody formation rates, and reduced theoretical risk of supraphysiologic IGF-1 levels. These advantages remain supported primarily by pharmacokinetic reasoning rather than head-to-head outcomes data.

Clinical Trial Evidence for Growth Velocity

The largest published dataset comes from the multicenter open-label trial by Thorner et al. (1996), which enrolled 110 pre-pubertal children with confirmed GHD (peak stimulated GH <10 ng/mL on two provocative tests). Subjects received sermorelin 30 mcg/kg subcutaneously at bedtime for 12 months [4].

Results showed mean first-year growth velocity increased from 3.8 cm/year at baseline to 8.1 cm/year (a net gain of 4.3 cm/year). Responders (defined as those achieving growth velocity above 6 cm/year) comprised 72% of subjects. Height velocity standard deviation score improved from -2.4 to -0.6 over the treatment period.

An earlier dose-ranging study by Duck et al. (1992) tested doses of 10, 30, and 60 mcg/kg in 56 children over 6 months. The 30 mcg/kg dose produced optimal response (5.2 cm/year acceleration) without additional benefit at 60 mcg/kg [5]. This finding established the dosing convention still used in compounding protocols.

Long-term extension data from Geref's original NDA submission (available via FDA archives) showed sustained growth velocity through 36 months in 64% of initial responders, though the magnitude of acceleration declined modestly in year two (7.4 cm/year) and year three (6.8 cm/year) [2]. No catch-up growth plateau was documented within the trial period.

How Sermorelin Compares to Recombinant Growth Hormone

No randomized head-to-head trial has directly compared sermorelin with modern rhGH formulations (somatropin) in a pediatric GHD population. The comparison relies on cross-trial analysis, which carries significant methodological limitations.

Recombinant GH at standard doses (0.025 to 0.05 mg/kg/day) typically produces first-year growth velocities of 10 to 12 cm/year in treatment-naive children with severe GHD [6]. Sermorelin's documented 8.1 cm/year places it at roughly 68 to 75% of rhGH efficacy by this indirect comparison. The gap narrows in partial GHD (peak stimulated GH 5-10 ng/mL), where rhGH responses are more modest and sermorelin's preserved pulsatility may offer proportionally better outcomes.

A retrospective chart review by Prakash and Goa (1999) examined 38 children who switched from sermorelin to somatropin after Geref supply interruptions. Growth velocity increased by an additional 1.8 cm/year after the switch, suggesting rhGH produces superior linear growth even in children who responded well to GHRH stimulation [7].

The 2019 Pediatric Endocrine Society consensus statement reaffirmed that recombinant GH is the first-line treatment for confirmed pediatric GHD. Dr. Alan Rogol, Professor Emeritus of Pediatrics at the University of Virginia, stated in a 2020 review: "GHRH analogs occupy a theoretical niche for children with hypothalamic GHD and intact somatotrophs, but the evidence base does not support their routine use over established rhGH protocols" [8].

Patient Selection: Who Might Benefit from Sermorelin

Sermorelin requires functional anterior pituitary somatotroph cells to work. Children with panhypopituitarism, pituitary aplasia, or post-surgical/post-radiation damage to the pituitary itself will not respond. The ideal candidate has hypothalamic GHD with preserved pituitary architecture.

Diagnostic confirmation involves two steps. First, standard GH stimulation testing (insulin tolerance test, arginine, clonidine, or glucagon) confirms GHD with peak GH <10 ng/mL. Second, a GHRH stimulation test demonstrates that the pituitary can respond to exogenous GHRH with adequate GH release (peak GH >10 ng/mL after GHRH bolus) [9]. This two-step approach identifies the subset of GHD children whose deficiency originates above the pituitary.

MRI findings supporting hypothalamic-level dysfunction include ectopic posterior pituitary bright spot, thin or interrupted pituitary stalk, and normal anterior pituitary volume. Children with these imaging features and positive GHRH stimulation tests represent the population most likely to respond to sermorelin therapy [10].

Contraindications parallel those of GH therapy: active malignancy, closed epiphyses, uncontrolled intracranial hypertension, and active proliferative or severe non-proliferative diabetic retinopathy. Sermorelin carries an additional relative contraindication in children with confirmed pituitary structural abnormalities (hypoplasia, empty sella) where somatotroph mass is reduced.

Dosing, Administration, and Monitoring

The historical FDA-approved dose was 30 mcg/kg body weight administered as a single subcutaneous injection at bedtime. Bedtime dosing aligns with the physiologic nocturnal GH surge and produces peak serum GH levels approximately 45 to 60 minutes post-injection [4].

Current compounding protocols generally follow this same convention. Reconstituted sermorelin is stored refrigerated (2-8°C) and administered via insulin syringe. Injection sites rotate among the abdomen, thigh, and upper arm.

Monitoring parameters during treatment include:

Growth velocity measured at 3-month intervals using a calibrated stadiometer. A response is typically defined as growth velocity exceeding 2 cm/year above pre-treatment baseline by month 6. Non-responders at 6 months are unlikely to benefit from continued therapy [5].

IGF-1 and IGFBP-3 levels measured every 3 to 6 months serve as biochemical markers of GH axis activation. Unlike exogenous rhGH, sermorelin-stimulated IGF-1 levels rarely exceed the age-adjusted upper normal range because the intact feedback loop limits GH oversecretion [11].

Bone age radiographs obtained annually assess skeletal maturation. A key monitoring concern with any GH-axis therapy is disproportionate skeletal advancement that could compromise final adult height. Available data suggest sermorelin advances bone age proportionally to height gain, maintaining the height-for-bone-age ratio [4].

Thyroid function testing (free T4, TSH) should occur at baseline and every 6 months, as GH axis stimulation can unmask central hypothyroidism requiring levothyroxine supplementation [3].

Safety Profile and Adverse Events

Sermorelin's safety database in pediatric populations spans approximately 800 treated children across all clinical development programs. The most common adverse events from the key trials were injection-site reactions (pain, erythema, swelling) in 17% of subjects, transient facial flushing in 9%, and headache in 6% [2].

Serious adverse events were rare. No cases of intracranial hypertension (pseudotumor cerebri) were reported in sermorelin trials, compared to an incidence of approximately 1 in 1,000 with rhGH therapy [12]. No increased malignancy risk was identified, though the total patient-years of exposure are far smaller than the rhGH safety database.

Anti-sermorelin antibodies developed in approximately 30% of subjects by 12 months. In most cases, these were non-neutralizing and did not correlate with diminished growth response. However, approximately 8% of children developed antibodies associated with attenuated clinical response, representing one mechanism of secondary treatment failure [4].

The theoretical safety advantage of sermorelin over rhGH lies in its inability to produce supraphysiologic GH or IGF-1 levels. Because the pituitary's own somatostatin-mediated feedback remains intact, GH release self-limits. Dr. Michael O. Thorner noted in the original Geref development program: "The GHRH analog approach provides an inherent safety ceiling that direct GH replacement cannot replicate, though this ceiling also constrains maximum efficacy" [4].

Regulatory and Access Considerations

Since Geref's discontinuation, sermorelin is available only through compounding pharmacies operating under FDA Section 503A (patient-specific prescriptions) or 503B (outsourcing facilities). The compound appears on the FDA's Drug Shortage list as discontinued rather than withdrawn for cause [13].

Compounded sermorelin is not subject to the same bioequivalence testing, stability verification, or potency standardization as commercially manufactured drugs. Quality varies between compounding pharmacies. Prescribers should verify that their pharmacy source holds current state board of pharmacy licensure, maintains third-party potency testing, and follows USP 797/800 standards for sterile compounding.

Insurance coverage for compounded sermorelin is inconsistent. Most commercial payers classify it as experimental/investigational for pediatric GHD given the absence of a current FDA-approved indication. Out-of-pocket costs range from $150 to $400 per month depending on the child's weight-based dose and pharmacy source.

The legal status of prescribing sermorelin off-label is straightforward: physicians may prescribe any legal drug off-label based on clinical judgment. The 2020 AACE/ACE guidance on hormone optimization acknowledges sermorelin's historical approval and acceptable safety profile while noting the evidence gap relative to current rhGH standards [14].

Current Guidelines and Evidence Gaps

The Endocrine Society (2016), Pediatric Endocrine Society (2019), and AACE (2020) guidelines unanimously recommend recombinant growth hormone as first-line therapy for pediatric GHD [3][14]. None currently recommend sermorelin as either first-line or second-line treatment.

The evidence gaps that would need to be filled for guideline inclusion include: a randomized controlled trial comparing sermorelin to somatropin with final adult height as the primary endpoint, standardized compounding quality assurance, and long-term safety data from registries comparable to the KIGS or NCGS databases that track rhGH outcomes [15].

Despite these gaps, a small subset of pediatric endocrinologists employ sermorelin in specific clinical scenarios: families who refuse daily rhGH injections but accept the slightly lower efficacy of GHRH stimulation, children with mild or partial GHD where the risk-benefit calculation for rhGH is less clear-cut, and as a GH-axis "priming" strategy before formal provocative testing in borderline cases.

The absence of patent protection and commercial manufacturer interest makes a modern registrational trial unlikely without NIH or foundation funding. Sermorelin's position in pediatric GHD therefore remains that of a historically validated but currently non-preferred off-label option with moderate supporting evidence.

Summary of Evidence Grade

Applying GRADE methodology to the available sermorelin-for-pediatric-GHD evidence yields a rating of moderate certainty (Grade B). The evidence is downgraded from high due to: observational/open-label study designs (no placebo-controlled RCTs for the growth indication), indirect comparisons to rhGH rather than direct head-to-head data, and the absence of final adult height outcomes [16]. The evidence is not downgraded further because results are consistent across studies, effect sizes are clinically meaningful, and the biological mechanism is well-characterized.

Pediatric endocrinologists considering sermorelin should document in the medical record: the specific reason rhGH is not being used, confirmation of hypothalamic-level GHD via GHRH stimulation testing, informed consent discussing off-label status and the evidence limitations, and a monitoring plan with defined response criteria and timeline for reassessment at 6 months.